| 研究実績の概要 |
We focused on the efficacy of β-glucan anti-tumor therapy combined with anti-PD-L1 mAb treatment, and the mechanism of their synergistic effects could be fully verified. In our mouse melanoma model, treatment with a PD-L1 blocking antibody with β-glucan synergized tumor regression. After treatment with β-glucan and anti-PD-L1 mAb antibody, tumor infiltrating leukocyte (TILs) not only showed a competent T cell function and CTL population but also showed enhanced tumor-recruited CD11b+ cell activity. This effect was also verified in the peritoneal exudate CD11b+ cells of tumor-bearing mice.
|
